Program
Caffeine
Also written as “caffeine”, “ibuprofen + caffeine” and “Paracetamol and Caffeine”.
Its studies are mostly in Pain · Neoplasms · Pain, Postoperative · Common Cold · Obesity, led by 6 companies.
Drug pageCaffeine: every studyMany companies study it; this page follows only the 16 they lead. All 247 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 60 open or running | phase 3since Aug 22, 2013 | Jun 13, 2013 | none ahead |
| GlaxoSmithKlineits history only | 50 open or running | phase 4since Nov 3, 2011 | Mar 1, 2007 | none ahead |
| Pfizerits history only | 20 open or running | phase 3since Aug 8, 2016 | Aug 8, 2016 | none ahead |
| Hypera Pharmaits history only | 10 open or running | phase 3since Jul 28, 2010 | Jul 28, 2010 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Aug 31, 2011 | Aug 31, 2011 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2013First study: phase 1 study in HealthyFirst studyNCT01879371 · 36 enrolled · Germany
- Aug 22, 2013Phase 3 study in Pain, PostoperativeNCT01929031 · 562 enrolled · United States
- Jul 7, 2014Phase 3 study in Migraine DisordersNCT02183688 · 1,889 enrolled
- Dec 10, 2015Phase 1 study in HealthyNCT02629354 · 36 enrolled · South Africa
- Nov 17, 2016Phase 3 study in Back PainNCT03003000 · 635 enrolled · Germany, Russian Federation
- Feb 14, 2023No phase study in Liver CirrhosisNCT05741385 · 4 enrolled · Germany
TargetBeta
“Adenosine receptor antagonist; Adenosine receptor antagonist”ChEMBL 37, by rule
Studies
All 6 Boehringer Ingelheim leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05741385Liver Cirrhosis · Germany | – | Completed | Aug 9, 2024 | 4 |
| NCT03003000Back Pain · Germany, Russian Federation | 3 | Completed | Sep 24, 2017 | 635 |
| NCT02629354Healthy · South Africa | 1 | Completed | Jan 2016 | 36 |
| NCT02183688Migraine Disorders | 3 | Completed | Jan 2003 | 1,889 |
| NCT01929031Pain, Postoperative · United States | 3 | Completed | Mar 2014 | 562 |
| NCT01879371Healthy · Germany | 1 | Completed | Jul 2013 | 36 |
How it is read
Names in the registry
- “Caffeine”, 11 entries
- “caffeine”, 4 entries
- “ibuprofen + caffeine”, 3 entries
- “Paracetamol and Caffeine”, 2 entries
- “Cocktail (Warfarin/Caffeine/Midazolam)”, 1 entry
Conditions, from the studies’ own filings
- Pain, 5 studies
- Neoplasms, 2 studies
- Pain, Postoperative, 2 studies
- Common Cold, 2 studies
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.